CL2009000452A1 - Oral disintegrating tablet comprising cilostazol, granulated particles that are prepared by uniform dispersion of an organic substance, a particulate disintegrating agent comprising two or more saccharides, a glidant, an organic excipient and optionally an additive; and method of preparing this tablet. - Google Patents

Oral disintegrating tablet comprising cilostazol, granulated particles that are prepared by uniform dispersion of an organic substance, a particulate disintegrating agent comprising two or more saccharides, a glidant, an organic excipient and optionally an additive; and method of preparing this tablet.

Info

Publication number
CL2009000452A1
CL2009000452A1 CL2009000452A CL2009000452A CL2009000452A1 CL 2009000452 A1 CL2009000452 A1 CL 2009000452A1 CL 2009000452 A CL2009000452 A CL 2009000452A CL 2009000452 A CL2009000452 A CL 2009000452A CL 2009000452 A1 CL2009000452 A1 CL 2009000452A1
Authority
CL
Chile
Prior art keywords
tablet
organic
cilostazol
glidant
saccharides
Prior art date
Application number
CL2009000452A
Other languages
Spanish (es)
Inventor
Okazaki Hidekazu
Kamada Naoki
Toda Masafumi
Fukami Tadashi
Koizumi Haruka
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of CL2009000452A1 publication Critical patent/CL2009000452A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Tableta desintegrante oral que comprende cilostazol, partículas granuladas que se preparan por dispersión uniforme de una sustancia orgánica, un agente desintegrante en partículas que comprenden dos o más sacáridos, un deslizante, un excipiente orgánico y opcionalmente un aditivo; y método para preparar esta tableta.Oral disintegrating tablet comprising cilostazol, granulated particles that are prepared by uniform dispersion of an organic substance, a particulate disintegrating agent comprising two or more saccharides, a glidant, an organic excipient and optionally an additive; and method of preparing this tablet.

CL2009000452A 2008-02-29 2009-02-27 Oral disintegrating tablet comprising cilostazol, granulated particles that are prepared by uniform dispersion of an organic substance, a particulate disintegrating agent comprising two or more saccharides, a glidant, an organic excipient and optionally an additive; and method of preparing this tablet. CL2009000452A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008050460 2008-02-29

Publications (1)

Publication Number Publication Date
CL2009000452A1 true CL2009000452A1 (en) 2010-03-26

Family

ID=40718911

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009000452A CL2009000452A1 (en) 2008-02-29 2009-02-27 Oral disintegrating tablet comprising cilostazol, granulated particles that are prepared by uniform dispersion of an organic substance, a particulate disintegrating agent comprising two or more saccharides, a glidant, an organic excipient and optionally an additive; and method of preparing this tablet.

Country Status (7)

Country Link
EP (1) EP2262487A2 (en)
JP (1) JP2011513194A (en)
AR (1) AR070530A1 (en)
CL (1) CL2009000452A1 (en)
PE (1) PE20091560A1 (en)
TW (1) TW200936184A (en)
WO (1) WO2009107864A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011158110A2 (en) 2010-04-28 2011-12-22 Nuformix Limited Cilostazol cocrystals and compositions
ES2422657B1 (en) * 2012-02-10 2014-06-11 Laboratorios Normon S.A. Cilostazol solid pharmaceutical composition
CN104487094B (en) 2012-07-20 2017-05-17 大塚制药株式会社 Tablet having dry-ink film on surface thereof, and ink for inkjet printer
JP5713421B1 (en) 2013-07-19 2015-05-07 株式会社三和化学研究所 Orally disintegrating tablets
US9974738B2 (en) 2013-09-27 2018-05-22 Daicel Corporation Disintegrating particle composition produced by two-stage wet granulation process, and intraorally disintegrating tablet containing same composition
US10231914B2 (en) * 2015-06-02 2019-03-19 Lynette Batton Effervescent tablet for elimination of red wine discoloration, offensive odour of mouth and cleaning the palate
EP3409294A1 (en) 2017-06-01 2018-12-05 Przedsiebiorstwo Farmaceutyczne Lek-Am Sp Z O. O. Tablets containing cilostazol of specific particle size distribution

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
WO2001076565A1 (en) * 2000-04-12 2001-10-18 Banyu Pharmaceutical Co., Ltd. Compositions disintegrating in oral cavity and preparations disintegrating in oral cavity
JP4637338B2 (en) * 2000-09-22 2011-02-23 大塚製薬株式会社 Cilostazol dry coated tablets
JP4551627B2 (en) * 2003-02-28 2010-09-29 東和薬品株式会社 Method for producing orally disintegrating tablets
IN234086B (en) * 2003-10-15 2009-05-29 Fuji Chem Ind Co Ltd
JP3841804B2 (en) * 2003-10-15 2006-11-08 富士化学工業株式会社 Composition for intraorally rapidly disintegrating tablets
TWI383809B (en) * 2005-06-29 2013-02-01 Otsuka Pharma Co Ltd Orally disintegrating powder comprising cilostazol
WO2007029376A1 (en) * 2005-09-02 2007-03-15 Fuji Chemical Industry Co., Ltd. Orally rapidly disintegrating tablet

Also Published As

Publication number Publication date
PE20091560A1 (en) 2009-10-30
JP2011513194A (en) 2011-04-28
WO2009107864A3 (en) 2009-12-03
WO2009107864A2 (en) 2009-09-03
EP2262487A2 (en) 2010-12-22
AR070530A1 (en) 2010-04-14
TW200936184A (en) 2009-09-01

Similar Documents

Publication Publication Date Title
CL2009000452A1 (en) Oral disintegrating tablet comprising cilostazol, granulated particles that are prepared by uniform dispersion of an organic substance, a particulate disintegrating agent comprising two or more saccharides, a glidant, an organic excipient and optionally an additive; and method of preparing this tablet.
PH12020550450A1 (en) Certain chemical entities, compositions and methods
CL2008003092A1 (en) Solid dispersion product comprising an active agent derived from n-aryl urea, a matrix-forming agent selected from cyclodextrins, polymers, lipids and a non-ionic surfactant; process for preparing said dispersion product; and a pharmaceutical dosage form comprising it.
MX2015017036A (en) Method for producing renal precursor cells, and drug containing renal precursor cells.
CO6781487A2 (en) Fast dispersion granules of oral disintegration tablets and methods
CR20120140A (en) CONTROLLED RELEASE COMPOSITIONS
AR069875A1 (en) TEMAZEPAM COMPOSITIONS FOR ORAL DISINTEGRATION TABLETS AND PREPARATION METHOD
CL2008001815A1 (en) Indazole derived compounds; process for preparing said compounds; pharmaceutical composition comprising them; and its use to treat cancer.
CL2008001753A1 (en) Process to prepare solid biomass for processing an aqueous mixture that comprises grinding the biomass, adding a dispersing agent and contacting it with a catalyst.
AR065721A1 (en) USED PIRIDAZINONE DERIVATIVES AS INHIBITORS OF GLUCANO SINTASA. PHARMACEUTICAL COMPOSITIONS.
CR11740A (en) COMPOSITIONS THAT INCLUDE SLIGHTLY BASIC DRUGS AND CONTROLLED RELEASE DOSAGE FORMS
CL2007002371A1 (en) METHOD FOR ADMINISTRATING A THERAPEUTIC AGENT THAT INCLUDES MANAGING A COMPOSITION OF NANOPARTICLES THAT INCLUDES A POLYMERIC MATRIX TOGETHER WITH A DIVALENT CATION CONTAINING A THERAPEUTIC AGENT; AND SUCH COMPOSITION.
IL219216A0 (en) A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
BRPI0819719A2 (en) Dipeptidyl peptidase-iv inhibition compounds, methods of preparing them, and pharmaceutical pepparations containing them as active agent
UY30308A1 (en) MGLUR5 V MODULATORS
AR063983A1 (en) FORMULATION OF CONTROLLED RELEASE OF AGONISTS AND ANTAGONISTS OF PIPERAZINE -PIPERIDINE OF THE 5-HT1A RECEPTOR THAT HAVE AN IMPROVED INTESTINAL DISSOLUTION
BR112013004829A2 (en) agricultural chemical dispersing agent composition, agricultural chemical composition, method for producing an agricultural product, method for increasing effectiveness in an agricultural chemical, and use of agricultural chemical dispersing agent composition.
AR067404A1 (en) GRANULAR COMPOUNDS OF INORGANIC AND LATEX REDISPERSABLE PARTICULATES IN POWDER AND METHODS
SA516371613B1 (en) Tablet Formulation for CGRP-Active Compounds
BRPI1007334A2 (en) compound, inhibitor, drug, pharmaceutical composition, use of a compound, anticancer agent, and method for treating cancer.
BRPI0920683A2 (en) Compound, composition of active compound, seed, drug, and methods for controlling phytopathogenic fungi, and for preparing an antimycotic agent.
RS53826B1 (en) Composition comprising powdered eggshell membrane for use in treating diabetes mellitus
CL2009002173A1 (en) Pharmaceutical composition with a pulsatile release of sildenafil having an immediate release fraction containing 5 to 100 mg of sildenafil and a controlled release fraction containing 25 to 150 mg of sildenafil; process to prepare it, useful to treat erectile dysfunction.
CL2008000675A1 (en) COMPOUNDS DERIVED FROM SULPHONYLED HETEROCICLES; METHOD FOR PREPARING SUCH COMPOUNDS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT BREAST CANCER, BETWEEN OTHER DISEASES.
NO20076120L (en) Stable nanoparticle formulations